Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading activity on Tuesday. Stock investors bought 15,360 call options on the stock. This represents an increase of 44% compared to the typical daily volume of 10,636 call options.

Insider Activity at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total transaction of $76,351.49. Following the transaction, the director now owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,341 shares of company stock worth $393,490. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its position in shares of Recursion Pharmaceuticals by 20.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company’s stock valued at $7,956,000 after buying an additional 178,994 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Recursion Pharmaceuticals by 25.7% during the second quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company’s stock worth $332,000 after buying an additional 9,058 shares during the period. Rhumbline Advisers grew its stake in shares of Recursion Pharmaceuticals by 24.1% in the second quarter. Rhumbline Advisers now owns 281,348 shares of the company’s stock valued at $2,110,000 after buying an additional 54,576 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the period. Finally, Arizona State Retirement System lifted its stake in Recursion Pharmaceuticals by 11.1% during the 2nd quarter. Arizona State Retirement System now owns 47,691 shares of the company’s stock worth $358,000 after acquiring an additional 4,760 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded down $0.35 during trading hours on Tuesday, reaching $7.60. The stock had a trading volume of 11,610,648 shares, compared to its average volume of 16,851,018. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74. The stock’s 50 day moving average is $6.89 and its 200 day moving average is $7.03. The firm has a market capitalization of $2.97 billion, a PE ratio of -4.97 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.43) EPS. Equities analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.